2020
DOI: 10.1016/j.vaccine.2019.11.002
|View full text |Cite
|
Sign up to set email alerts
|

Skin thickness measurements for optimal intradermal injections in children

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
7
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(7 citation statements)
references
References 22 publications
0
7
0
Order By: Relevance
“…An increase in microneedle height can lead to intensified pain [9]. Van Mulder et al reported that the optimal microneedle height should not exceed 700 μm for application in children ages: 8 weeks to 18 years old [12]. While Gill et al concluded that the microneedle width base does not significantly impact pain, the shape of the base compromises the insertion into the skin [9].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…An increase in microneedle height can lead to intensified pain [9]. Van Mulder et al reported that the optimal microneedle height should not exceed 700 μm for application in children ages: 8 weeks to 18 years old [12]. While Gill et al concluded that the microneedle width base does not significantly impact pain, the shape of the base compromises the insertion into the skin [9].…”
Section: Discussionmentioning
confidence: 99%
“…Additionally, Nalluri et al showed that a 1.5 mm height demonstrated the best cell activation in the dermis, increasing drug absorption [11]. Van Mulder et al demonstrated that needle length should not exceed 700 μm to guarantee intradermal puncture in children [12].…”
Section: Introductionmentioning
confidence: 99%
“…33 Although skin thickness at this age does not differ between the sexes, the influence of sex hormones on the Th1/Th2 cytokine pattern or the presence of estrogen receptors on lymphocytes and macrophages could influence the susceptibility to infectious disorders, including scabies. 34 Possible future therapeutic options for scabies in infants include the macrocyclic lactone moxidectin, which has shown high effectiveness against Sarcoptes scabiei in vitro and in animal models and is currently being evaluated for use against human scabies. 35,36 off-label J o u r n a l P r e -p r o o f 14 administration of ivermectin to infants of <15 kg body weight was reported to be welltolerated.…”
Section: Discussionmentioning
confidence: 99%
“…However, thickness measurements of children's skin of legs and arms below 2 mm were reported (Waller and Maibach 2005). Relatively recent studies also indicated an overall skin thickness increase with age at various anatomical locations (Derraik et al 2014, Van Mulder et al 2020. Combined with a predicted lower effective dose, the STT data point to a more plausible in vivo bone Pb LXRF in children.…”
Section: In Vivo Bone Pb Measurements Considerationsmentioning
confidence: 98%